HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET

January 5, 2019

On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based CRT or radiotherapy plus cetuximab. Compared with the standard of care regimen, cetuximab showed no toxicity benefit, and negatively impacted tumor control. https://pubmed.ncbi.nlm.nih.gov/30449623/

Recent Posts

See All

ARTICLE ON THE FORMATION OF THE HNCIG PUBLISHED IN ORAL ONCOLOGY

July 10, 2017 An article describing the formation of the HNCIG as well as its objectives, structure, and activities was published in Oral...

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK July 15, 2020...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED...

HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET

Recent Posts

Comments